Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 8Breast Neoplasms 8Multiple Myeloma 6Giant Cell Tumor of Bone 6Prostatic Neoplasms 5Fractures, Bone 4Neoplasm Metastasis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Osteoporosis 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Bone Metastases 2Bone Diseases 2Thyroid Neoplasms 1Recurrence 1Parathyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hormone Refractory Prostate Cancer 1Hodgkin Disease 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Denosumab × Clear all
NCT00259740 2017-03-15

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Amgen

Phase 2 Completed
96 enrolled 7 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡